MedTrace Logo

Mass Balance Study of NV-5138 in Healthy Male Subjects.

NCT05152680 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-03-15

No results posted yet for this study

Summary

The objective of this study is to assess the mass balance and routes of excretion of total radioactivity after a single oral dose of 1600 mg \[14C\]-NV-5138.

Conditions

  • Healthy Volunteers

Interventions

DRUG

[14C]-NV-5138

Single dose, given as oral solution, 1600 mg

Sponsors & Collaborators

  • Supernus Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Navitor Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-11
Primary Completion
2021-12-09
Completion
2021-12-09

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05152680 on ClinicalTrials.gov